6,963 publications from this institution
COPD is a major and increasing global health problem, which is predicted to become the third commonest cause of death and the fifth commonest cause of disability in the world by 2020 (1). Indeed the World Health Organization has already demonstrated that COPD is now ranked as the fourth commonest cause of death worldwide (2). COPD is the only common cause of death in the United States of America that has increased over the last 20 years and in the UK it now causes over 30,000 deaths a year (3).
No abstract is provided for this article.
Restenosis following coronary stent implantation remains an important and costly therapeutic problem. Since intimal smooth muscle cell (SMC) proliferation is largely the culprit,1-4 various attempts to inhibit this process have been studied.5-10 Modulation of the stimuli for neointimal hyperplasia by appropriate pharmacologic agents would, in theory, permit vessel wall healing after coronary stent implantation without an exaggerated, obstructive proliferative response. Until recently, local drug delivery, using various agents and different methods of administration, has failed to affect restenosis rate after stenting (see further the discussion in Chapter 29).11,12 This may be related to the agent studied, and the design of the delivery device, as well as the timing of drug delivery with respect to stenting. Arterial injury triggers thrombus formation with release of growth factors known to stimulate neointimal proliferation: platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β, fibroblast growth factor (FGF) and others.13-15STUDIESEnoxaparin has been shown to inhibit smooth muscle cell proliferation at high tissue concentrations.16-18 However, it has not reduced the incidence of angiographic restenosis or clinical events after successful coronary angioplasty when administered systemically.19 In a baboon angioplasty model low molecular weight heparin (LMWH) blocked seruminduced but not PDGF-induced SMC proliferation and migration, suggesting heparin sensitive and insensitive pathways. If the assumption that human SMC are less sensitive to growth inhibition by heparin is true, one may consider the possibility that in-stent restenosis may be reduced by local prevention of early prothrombotic events. Enoxaparin is a potent inhibitor of factor Xa and thrombin.20,21 The strategy of local delivery of enoxaparin during predilation was specifically designed to modulate the magnitude of thrombin-mediated and thrombus-mediated stimuli for neointimal proliferation. The purpose of enoxaparin delivery during predilation is to have an antithrombotic agent in place at the time of the initial balloon deflation, when the injured vessel wall was first exposed to circulating prothrombotic elements. This hypothesis was tested in an atherosclerotic rabbit model where 10 mg of enoxaparin delivered during iliacangioplasty reduced neointimal proliferation as evidenced by reduced BRDU uptake compared with conventional angioplasty.18
No abstract is provided for this article.
No abstract is provided for this article.
The immediate and short-term results of coronary angioplasty were analysed in 16 patients who presented with chest pain at rest associated with transient marked ST-segment elevation (greater than or equal to 0.5 mV). The number of in hospital ischaemic attacks was on average 2.8 (range 1-8). All patients had at least one haemodynamically significant coronary artery stenosis for angioplasty. Multivessel coronary artery disease was present in 37% (6 of 16 patients). Before angioplasty the patients were premedicated with a combination of nitroglycerin, calcium-antagonists and beta-receptor blockers. The initial success rate was 87% (14 of 16 patients). There were no deaths and no urgent CABG. Two patients sustained a procedure related myocardial infarction; in one patient a cerebrovascular accident occurred. After a mean follow-up of 13 +/- 8 months (range 3-25) angina had recurred in 19% (3 of 16 patients). One patient died due to carcinoma of the lung. Repeat angiography was performed 3.2 +/- 1.7 months after the procedure. Angiographic restenosis had occurred in 27% (4 of 15 patients) at this time. These results suggest that angioplasty in these patients is effective in relieving ischaemic symptoms and in preventing progression to myocardial infarction.
It is now well established that inflammation is of critical importance in asthma and this has been a major impetus to changing the management of asthma, with emphasis on the early use of anti-inflammatory treatments. Inflammation is also important in COPD; chronic inflammation is present in the airways and lung parenchyma of patients with COPD, although the pathophysiologic significance of this inflammation is currently uncertain. The inflammatory process in COPD differs in most respects from that in asthma in terms of inflammatory cells, inflammatory mediators, inflammatory responses and response to corticosteroid therapy.1 However, some patients with COPD (10%) also have asthma and therefore may share inflammatory features. Cigarette smoking itself induces an inflammatory response and the inflammatory changes described in COPD appear to be an exaggeration of the normal inflammatory response to an irritant.2 More comparisons between COPD patients and individuals with normal lung function who are matched for smoking exposure are needed. It is also important to differentiate COPD from asthma, and a negative trial of corticosteroids is recommended in selecting suitable patients for study. There is little information about the inflammatory process in patients with COPD that is not due to smoking.3